Comparative Efficacy of Resmetirom, GLP-1 Receptor Agonists, and Pioglitazone for Fibrosis Regression and MASH Resolution in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Narrative Synthesis of Network Meta-Analyses with Implications for Pakistan
DOI:
https://doi.org/10.63521/641kea29Keywords:
Metabolic Dysfunction-Associated Steatohepatitis, Resmetirom, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Pioglitazone, FibrosisAbstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent a rapidly growing public health challenge in Pakistan and South Asia due to rising prevalence of obesity, type 2 diabetes, and metabolic syndrome. Pharmacological options beyond lifestyle modification are essential for patients with moderate-to-advanced fibrosis (F2–F3). This systematic review synthesizes comparative efficacy data on resmetirom (thyroid hormone receptor-β agonist), GLP-1 receptor agonists (e.g., semaglutide), and pioglitazone for key histological endpoints: MASH resolution without worsening of fibrosis and fibrosis improvement (≥1 stage) without worsening of MASH.
Methods: Following PRISMA guidelines, a systematic search was conducted in PubMed, Embase, PMC, PakMediNet, and Google Scholar from January 2015 to July 2025. Eligible studies included phase 3 randomized controlled trials (RCTs) and network meta-analyses reporting histological outcomes in biopsy-proven MASH. Data on responder rates, relative risks (RR), odds ratios (OR), and surface under the cumulative ranking curve (SUCRA) rankings were extracted from high-quality sources. Random-effects model summaries and heterogeneity assessments (I²) were noted from published network meta-analyses. Pakistan-specific epidemiological and access data were integrated for contextual relevance.
Results: Network meta-analyses (29 RCTs, n>9,000) ranked pegozafermin highest for both endpoints, followed by tirzepatide, resmetirom, and semaglutide. In MAESTRO-NASH (n=966, F2–F3), resmetirom 100 mg achieved MASH resolution in 29.9% vs. 9.7% placebo and fibrosis improvement in 25.9% vs. 14.2% placebo. In ESSENCE (interim, n=800 at week 72), semaglutide 2.4 mg achieved MASH resolution in 62.9% vs. 34.3% placebo and fibrosis improvement in 36.8% vs. 22.4% placebo. Pioglitazone showed modest effects (RR 2.29 for resolution). In Pakistan, MASLD prevalence ranges 14–38.9%, with limited access to newer agents.
Conclusions: Resmetirom and GLP-1 RAs demonstrate superior histological efficacy compared to pioglitazone. In resource-limited settings like Pakistan, a tiered approach prioritizing affordable therapies, non-invasive monitoring, and local research is recommended to address the growing burden.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Sameed Qureshi, Kamran Amir Khan, Aamir Wisal, Ramsha Khan, Hamza Ahmad (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the Pakistan Journal of Gastroenterology (PJG) the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
